State Street’s Immune Design Corp. IMDZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-597,011
Closed -$3.49M 3919
2019
Q1
$3.49M Sell
597,011
-64,765
-10% -$221K ﹤0.01% 2922
2018
Q4
$860K Buy
661,776
+109,242
+20% +$190K ﹤0.01% 3356
2018
Q3
$1.9M Buy
552,534
+86,375
+19% +$324K ﹤0.01% 3264
2018
Q2
$2.12M Buy
466,159
+73,326
+19% +$292K ﹤0.01% 3232
2018
Q1
$1.3M Buy
392,833
+151,155
+63% +$535K ﹤0.01% 3297
2017
Q4
$942K Buy
241,678
+20,188
+9% +$110K ﹤0.01% 3366
2017
Q3
$2.29M Sell
221,490
-2,542
-1% -$25K ﹤0.01% 3145
2017
Q2
$2.18M Sell
224,032
-992
-0.4% -$6.96K ﹤0.01% 3099
2017
Q1
$1.53M Sell
225,024
-12,539
-5% -$72.5K ﹤0.01% 3176
2016
Q4
$1.31M Buy
237,563
+18,115
+8% +$128K ﹤0.01% 3227
2016
Q3
$1.67M Buy
219,448
+11,778
+6% +$86.1K ﹤0.01% 3042
2016
Q2
$1.69M Buy
207,670
+39,551
+24% +$493K ﹤0.01% 3094
2016
Q1
$2.19M Buy
168,119
+43,026
+34% +$497K ﹤0.01% 2973
2015
Q4
$2.51M Buy
125,093
+16,404
+15% +$283K ﹤0.01% 2906
2015
Q3
$1.32M Buy
108,689
+22,640
+26% +$424K ﹤0.01% 3147
2015
Q2
$1.77M Buy
86,049
+12,185
+16% +$288K ﹤0.01% 3098
2015
Q1
$1.56M Buy
73,864
+8,622
+13% +$225K ﹤0.01% 3114
2014
Q4
$2.01M Buy
65,242
+22,342
+52% +$621K ﹤0.01% 3041
2014
Q3
$757K Buy
+42,900
New +$543K ﹤0.01% 3316

State Street's IMDZ Position: Q2 2019 in Review

State Street sold out of Immune Design Corp. (IMDZ) in Q2 2019, closing a stake of 597,011 shares — an estimated $3.49M sold.

State Street first reported a position in IMDZ in Q3 2014 and held it in 19 quarters. The position peaked at $3.49M in Q1 2019. 0 funds tracked by Wall St. Rank hold IMDZ as of Q2 2019.

  • State Street reported no remaining Immune Design Corp. position as of Q2 2019 after selling out during the quarter.
  • State Street sold 597,011 Immune Design Corp. shares in Q2 2019, an estimated $3.49M.
  • State Street first reported a position in Immune Design Corp. in Q3 2014 and held it in 19 quarters.
  • State Street's Immune Design Corp. position peaked at $3.49M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2019.

Based on State Street's 13F filing for Q2 2019, filed 14 Aug 2019.